[ { "digest_date": "2026-04-29", "window_start": "2026-04-28T05:15:00.000Z", "window_end": "2026-04-29T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 82, "id": "sec:0001817713:0001193125-26-187641:8-K", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/1817713/000119312526187641/janx-20260428.htm", "headline": "Janux: 8-K filing", "summary": "Janux filed material event report on 2026-04-28. TCR/pMHC company watchlist entry; modalities: TCE (non TCR); targets: PSMA, EGFR", "url": "https://www.sec.gov/Archives/edgar/data/1817713/000119312526187641/janx-20260428.htm", "source": "SEC EDGAR", "published_date": "2026-04-28", "match_reason": "Direct pMHC or peptide-MHC targeting: pmhc | Watchlist company material event: sec filing, 8-k, material event", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Janux", "drug_name": "", "event_type": "material event report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 8-k; material event report; Janux; TCR/pMHC company watchlist entry; modalities: TCE (non TCR); targets: PSMA, EGFR; Janux; JANX007; JANX008; JANX007; JANX008; PSMA; EGFR" }, { "digest_date": "2026-04-30", "window_start": "2026-04-29T05:15:00.000Z", "window_end": "2026-04-30T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 46, "id": "news:https://www.statnews.com/pharmalot/2026/04/29/fda-plan-to-speed-clinical-trials-supreme-court-skinny-labels/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/pharmalot/2026/04/29/fda-plan-to-speed-clinical-trials-supreme-court-skinny-labels", "headline": "STAT+: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more", "summary": "The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials conducted by AstraZeneca and Amgen", "url": "https://www.statnews.com/pharmalot/2026/04/29/fda-plan-to-speed-clinical-trials-supreme-court-skinny-labels/?utm_campaign=rss", "source": "STAT Pharma", "published_date": "2026-04-29T13:09:22.000Z", "match_reason": "Clinical or translational importance: clinical trial | Watchlist hits: AstraZeneca", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "STAT Pharma", "secondary_coverage": "", "keywords": "news; STAT Pharma; regulatory" }, { "digest_date": "2026-04-30", "window_start": "2026-04-29T05:15:00.000Z", "window_end": "2026-04-30T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 2, "score": 42, "id": "news:https://www.statnews.com/2026/04/29/biotech-news-a-patent-win-for-pfizer-and-bridgebio/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/2026/04/29/biotech-news-a-patent-win-for-pfizer-and-bridgebio", "headline": "STAT+: A patent win for Pfizer and BridgeBio", "summary": "A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout", "url": "https://www.statnews.com/2026/04/29/biotech-news-a-patent-win-for-pfizer-and-bridgebio/?utm_campaign=rss", "source": "STAT Biotech", "published_date": "2026-04-29T13:43:25.000Z", "match_reason": "Clinical or translational importance: clinical trial", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "clinical data", "primary_source": "STAT Biotech", "secondary_coverage": "", "keywords": "news; STAT Biotech; clinical data" }, { "digest_date": "2026-05-01", "window_start": "2026-04-30T05:15:00.000Z", "window_end": "2026-05-01T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 100, "id": "sec:0002000410:0001213900-26-050570:S-4", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/2000410/000121390026050570/ea0286623-s4_eureka.htm", "headline": "Eureka Therapeutics: S-4 filing", "summary": "Eureka Therapeutics filed business combination registration statement on 2026-05-01. TCR/pMHC company watchlist entry; modalities: abTCR-T; targets: AFP, WT1", "url": "https://www.sec.gov/Archives/edgar/data/2000410/000121390026050570/ea0286623-s4_eureka.htm", "source": "SEC EDGAR", "published_date": "2026-05-01", "match_reason": "Direct pMHC or peptide-MHC targeting: pmhc | TCR therapeutic modality: tcr-t | Watchlist company material event: sec filing, registration statement", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Eureka Therapeutics", "drug_name": "", "event_type": "business combination registration statement", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; s-4; business combination registration statement; Eureka Therapeutics; TCR/pMHC company watchlist entry; modalities: abTCR-T; targets: AFP, WT1; Eureka Therapeutics; AFP; WT1" }, { "digest_date": "2026-05-01", "window_start": "2026-04-30T05:15:00.000Z", "window_end": "2026-05-01T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 2, "score": 82, "id": "sec:0001645460:0001193125-26-198588:8-K", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/1645460/000119312526198588/d128047d8k.htm", "headline": "Cue Biopharma: 8-K filing", "summary": "Cue Biopharma filed material event report on 2026-05-01. TCR/pMHC company watchlist entry", "url": "https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/d128047d8k.htm", "source": "SEC EDGAR", "published_date": "2026-05-01", "match_reason": "Direct pMHC or peptide-MHC targeting: pmhc | Watchlist company material event: sec filing, 8-k, material event", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Cue Biopharma", "drug_name": "", "event_type": "material event report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 8-k; material event report; Cue Biopharma; TCR/pMHC company watchlist entry; Cue Biopharma" }, { "digest_date": "2026-05-01", "window_start": "2026-04-30T05:15:00.000Z", "window_end": "2026-05-01T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 3, "score": 28, "id": "news:https://www.statnews.com/pharmalot/2026/04/30/supreme-court-hearing-skinny-labels-astrazeneca-uk-expansion/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/pharmalot/2026/04/30/supreme-court-hearing-skinny-labels-astrazeneca-uk-expansion", "headline": "STAT+: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and more", "summary": "AstraZeneca will resume expansion of its U.K. R&D operations after the trade deal with the U.S. included measures to lift U.K. drug spending", "url": "https://www.statnews.com/pharmalot/2026/04/30/supreme-court-hearing-skinny-labels-astrazeneca-uk-expansion/?utm_campaign=rss", "source": "STAT Pharma", "published_date": "2026-04-30T13:17:31.000Z", "match_reason": "Watchlist hits: AstraZeneca", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "STAT Pharma", "secondary_coverage": "", "keywords": "news; STAT Pharma; news" }, { "digest_date": "2026-05-02", "window_start": "2026-05-01T05:15:00.000Z", "window_end": "2026-05-02T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 28, "id": "news:https://www.statnews.com/pharmalot/2026/05/01/obesity-drugs-excluded-from-compounding-list-astrazeneca-setback/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/pharmalot/2026/05/01/obesity-drugs-excluded-from-compounding-list-astrazeneca-setback", "headline": "STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more", "summary": "The FDA proposed excluding the active ingredients in popular obesity and diabetes drugs from a list of substances that can be used for compounded versions", "url": "https://www.statnews.com/pharmalot/2026/05/01/obesity-drugs-excluded-from-compounding-list-astrazeneca-setback/?utm_campaign=rss", "source": "STAT Pharma", "published_date": "2026-05-01T13:45:35.000Z", "match_reason": "Watchlist hits: AstraZeneca", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "STAT Pharma", "secondary_coverage": "", "keywords": "news; STAT Pharma; regulatory" }, { "digest_date": "2026-05-02", "window_start": "2026-05-01T05:15:00.000Z", "window_end": "2026-05-02T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 2, "score": 28, "id": "news:https://www.biopharmadive.com/news/summit-ivonescimab-esperion-axsome-alzheimers-astrazeneca-camizestrant/819031/", "canonical_key": "url:https://www.biopharmadive.com/news/summit-ivonescimab-esperion-axsome-alzheimers-astrazeneca-camizestrant/819031", "headline": "Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal", "summary": "Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.", "url": "https://www.biopharmadive.com/news/summit-ivonescimab-esperion-axsome-alzheimers-astrazeneca-camizestrant/819031/", "source": "BioPharma Dive", "published_date": "2026-05-01T16:28:00.000Z", "match_reason": "Watchlist hits: AstraZeneca", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; regulatory" }, { "digest_date": "2026-05-02", "window_start": "2026-05-01T05:15:00.000Z", "window_end": "2026-05-02T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 3, "score": 24, "id": "news:https://endpoints.news/qa-seaport-ceo-and-cso-on-learning-from-karuna-and-the-future-of-cns-research/", "canonical_key": "url:https://endpoints.news/qa-seaport-ceo-and-cso-on-learning-from-karuna-and-the-future-of-cns-research", "headline": "Q&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research", "summary": "Company: T Therapeutics. Seaport Therapeutics began trading as a public company on Friday after executives rang the Nasdaq’s opening bell. Shares rose {$SPTX} more than 20%. With a team largely made up of Karuna Therapeutics veterans, Seaport is ...", "url": "https://endpoints.news/qa-seaport-ceo-and-cso-on-learning-from-karuna-and-the-future-of-cns-research/", "source": "Endpoints News", "published_date": "2026-05-01T16:50:12.000Z", "match_reason": "Matched broad pMHC/TCR collection terms but needs editorial review.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "T Therapeutics", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; T Therapeutics; news" }, { "digest_date": "2026-05-04", "window_start": "2026-05-03T05:15:00.000Z", "window_end": "2026-05-04T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 42, "id": "clinicaltrials:NCT06871683", "canonical_key": "url:https://clinicaltrials.gov/study/nct06871683", "headline": "ClotTriever® Thrombectomy System Use-Result Survey in Japan", "summary": "Company: Inari Medical | Drug/program: ClotTriever® Thrombectomy System. The objective of this survey is to determine the safety and efficacy of the ClotTriever Thrombectomy System under daily clinical practice after marketing approval in Japan.", "url": "https://clinicaltrials.gov/study/NCT06871683", "source": "ClinicalTrials.gov", "published_date": "2026-05-04", "match_reason": "Clinical or translational importance: clinical trial, safety", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Inari Medical", "drug_name": "ClotTriever® Thrombectomy System", "event_type": "clinical trial update", "primary_source": "ClinicalTrials.gov", "secondary_coverage": "", "keywords": "clinical trial; Deep Vein Thrombosis; Inari Medical; ClotTriever® Thrombectomy System" }, { "digest_date": "2026-05-06", "window_start": "2026-05-05T05:15:00.000Z", "window_end": "2026-05-06T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 100, "id": "sec:0001671927:0001671927-26-000009:10-Q", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/1671927/000167192726000009/imcr-20260331.htm", "headline": "Immunocore: 10-Q filing", "summary": "Immunocore filed quarterly report on 2026-05-06. Programs mentioned: KIMMTRAK, tebentafusp, brenetafusp, IMC-M113V, IMC-P115C. Targets mentioned: PRAME, GAG. Relevant filing language: tentially available relevant information. Forward-looking statements include, but are not limited to, statements about: the therapeutic potential and expected clinical benefits of KIMMTRAK®; the planned geographic expansion and expansion of patient reach for KIMMTRAK; the plans for expansion and growth into new melanoma indications, beyond melanoma into other tumor types, and beyond oncology;", "url": "https://www.sec.gov/Archives/edgar/data/1671927/000167192726000009/imcr-20260331.htm", "source": "SEC EDGAR", "published_date": "2026-05-06", "match_reason": "Direct pMHC or peptide-MHC targeting: pmhc | Clinical or translational importance: clinical trial | Watchlist company material event: sec filing, quarterly report", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Immunocore", "drug_name": "KIMMTRAK, tebentafusp, brenetafusp, IMC-M113V, IMC-P115C, IMC-R117C, IMC-S118AI, IMC-U120AI", "event_type": "quarterly report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 10-q; quarterly report; Immunocore; IMCR; soluble TCR and pMHC-targeting therapeutics; Immunocore; KIMMTRAK; tebentafusp; brenetafusp; IMC-F106C; IMC-I109V; IMC-M113V; Brenetafusp (IMC-F106C); IMC-P115C; IMC-T119C; IMC-R117C; IMC-S118AI; IMC-U120AI; KIMMTRAK; tebentafusp; brenetafusp; IMC-F106C; IMC-I109V; IMC-M113V; Brenetafusp (IMC-F106C); IMC-P115C; IMC-T119C; IMC-R117C; IMC-S118AI; IMC-U120AI; gp100; PRAME; PRAME-HLE; PIWIL1; GAG; HBV Envelope; PPI; CD1a; KIMMTRAK; tebentafusp; brenetafusp; IMC-M113V; IMC-P115C; IMC-R117C; IMC-S118AI; IMC-U120AI; PRAME; GAG; clinical trial; enrollment; FDA; EMA; liquidity; termination" }, { "digest_date": "2026-05-06", "window_start": "2026-05-05T05:15:00.000Z", "window_end": "2026-05-06T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 2, "score": 100, "id": "sec:0001783328:0001193125-26-207572:10-Q", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/1783328/000119312526207572/tcrx-20260331.htm", "headline": "TScan Therapeutics: 10-Q filing", "summary": "TScan Therapeutics filed quarterly report on 2026-05-06. Programs mentioned: TSC-100, TSC-101, T-Plex, TSC-102, TScan. Targets mentioned: HA-2, CD45. Relevant filing language: designation. We have obtained and may continue to seek an RMAT designation for some of our product candidates. In May 2024, we announced that the FDA granted RMAT designation for TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing HCT with reduced intensity conditioning.", "url": "https://www.sec.gov/Archives/edgar/data/1783328/000119312526207572/tcrx-20260331.htm", "source": "SEC EDGAR", "published_date": "2026-05-06", "match_reason": "TCR therapeutic modality: tcr-t | Clinical or translational importance: clinical trial, dose escalation | Watchlist company material event: sec filing, quarterly report", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "TScan Therapeutics", "drug_name": "TSC-100, TSC-101, T-Plex, TSC-102, TScan", "event_type": "quarterly report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 10-q; quarterly report; TScan Therapeutics; TCRX; TCR-T target discovery and cell therapy programs; TScan; TScan Therapeutics; TSC-100; TSC-101; TSC-200; TSC-201; T-Plex; TSC-102; TSC-202; TSC-203; TSC-204; TSC-100; TSC-101; TSC-200; TSC-201; T-Plex; TSC-102; TSC-202; TSC-203; TSC-204; HA-1; HA-2; CD45; HPV16; MAGE-C2; MAGE-A4; PRAME; MAGE-A1; TSC-100; TSC-101; T-Plex; TSC-102; TScan; HA-2; CD45; clinical trial; dose escalation; enrollment; adverse event; clinical hold; FDA; EMA; going concern; liquidity; restructuring; termination" }, { "digest_date": "2026-05-06", "window_start": "2026-05-05T05:15:00.000Z", "window_end": "2026-05-06T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 3, "score": 98, "id": "sec:0001671927:0001140361-26-019205:8-K", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/1671927/000114036126019205/ef20072537_8k.htm", "headline": "Immunocore: 8-K filing", "summary": "Immunocore filed material event report on 2026-05-06. soluble TCR and pMHC-targeting therapeutics", "url": "https://www.sec.gov/Archives/edgar/data/1671927/000114036126019205/ef20072537_8k.htm", "source": "SEC EDGAR", "published_date": "2026-05-06", "match_reason": "Direct pMHC or peptide-MHC targeting: pmhc | Watchlist company material event: sec filing, 8-k, material event | Watchlist hits: Immunocore, soluble TCR, PRAME, gp100", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Immunocore", "drug_name": "", "event_type": "material event report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 8-k; material event report; Immunocore; IMCR; soluble TCR and pMHC-targeting therapeutics; Immunocore; KIMMTRAK; tebentafusp; brenetafusp; IMC-F106C; IMC-I109V; IMC-M113V; Brenetafusp (IMC-F106C); IMC-P115C; IMC-T119C; IMC-R117C; IMC-S118AI; IMC-U120AI; KIMMTRAK; tebentafusp; brenetafusp; IMC-F106C; IMC-I109V; IMC-M113V; Brenetafusp (IMC-F106C); IMC-P115C; IMC-T119C; IMC-R117C; IMC-S118AI; IMC-U120AI; gp100; PRAME; PRAME-HLE; PIWIL1; GAG; HBV Envelope; PPI; CD1a" }, { "digest_date": "2026-05-06", "window_start": "2026-05-05T05:15:00.000Z", "window_end": "2026-05-06T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 4, "score": 96, "id": "sec:0001783328:0001193125-26-207549:8-K", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/1783328/000119312526207549/tcrx-20260506.htm", "headline": "TScan Therapeutics: 8-K filing", "summary": "TScan Therapeutics filed material event report on 2026-05-06. TCR-T target discovery and cell therapy programs", "url": "https://www.sec.gov/Archives/edgar/data/1783328/000119312526207549/tcrx-20260506.htm", "source": "SEC EDGAR", "published_date": "2026-05-06", "match_reason": "TCR therapeutic modality: tcr-t | Watchlist company material event: sec filing, 8-k, material event | Watchlist hits: TScan, TCR-T, PRAME, MAGE-A4, MAGE-A1", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "TScan Therapeutics", "drug_name": "", "event_type": "material event report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 8-k; material event report; TScan Therapeutics; TCRX; TCR-T target discovery and cell therapy programs; TScan; TScan Therapeutics; TSC-100; TSC-101; TSC-200; TSC-201; T-Plex; TSC-102; TSC-202; TSC-203; TSC-204; TSC-100; TSC-101; TSC-200; TSC-201; T-Plex; TSC-102; TSC-202; TSC-203; TSC-204; HA-1; HA-2; CD45; HPV16; MAGE-C2; MAGE-A4; PRAME; MAGE-A1" }, { "digest_date": "2026-05-06", "window_start": "2026-05-05T05:15:00.000Z", "window_end": "2026-05-06T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 5, "score": 50, "id": "news:https://endpoints.news/second-life-for-gene-therapy-takeda-phase-2-3-win-uk-cancer-biotechs-83m/", "canonical_key": "url:https://endpoints.news/second-life-for-gene-therapy-takeda-phase-2-3-win-uk-cancer-biotechs-83m", "headline": "Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83M", "summary": "A blood test might predict who will respond to Wegovy; Viridian's thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 Second life for a gene therapy: A Cleveland-based biotech called ...", "url": "https://endpoints.news/second-life-for-gene-therapy-takeda-phase-2-3-win-uk-cancer-biotechs-83m/", "source": "Endpoints News", "published_date": "2026-05-05T15:37:27.000Z", "match_reason": "Clinical or translational importance: phase 2 | Watchlist hits: GSK, Takeda", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "clinical data", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; clinical data" }, { "digest_date": "2026-05-06", "window_start": "2026-05-05T05:15:00.000Z", "window_end": "2026-05-06T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 1, "score": 24, "id": "news:https://endpoints.news/pfizer-ends-trillium-related-development-as-rd-spend-jumps/", "canonical_key": "url:https://endpoints.news/pfizer-ends-trillium-related-development-as-rd-spend-jumps", "headline": "Pfizer ends Trillium-related development as R&D spend jumps", "summary": "Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and obesity studies. The company reported in", "url": "https://endpoints.news/pfizer-ends-trillium-related-development-as-rd-spend-jumps/", "source": "Endpoints News", "published_date": "2026-05-05T14:41:28.000Z", "match_reason": "Matched broad pMHC/TCR collection terms but needs editorial review.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; news" }, { "digest_date": "2026-05-07", "window_start": "2026-05-06T05:15:00.000Z", "window_end": "2026-05-07T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 100, "id": "sec:0001789972:0001193125-26-210304:10-Q", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/1789972/000119312526210304/cgem-20260331.htm", "headline": "Cullinan (w/ fred hutch): 10-Q filing", "summary": "Cullinan (w/ fred hutch) filed quarterly report on 2026-05-07. Programs mentioned: Cullinan. Relevant filing language: 3-31 0001789972 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001789972 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001789972 us-gaap:CollaborativeArrangementMember cgem:CullinanMember 2026-01-01 2026-03-31 0001789972 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001789972 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0001789972 us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001789972 us-ga clinical-stage product candidates;", "url": "https://www.sec.gov/Archives/edgar/data/1789972/000119312526210304/cgem-20260331.htm", "source": "SEC EDGAR", "published_date": "2026-05-07", "match_reason": "Direct pMHC or peptide-MHC targeting: pmhc | Clinical or translational importance: clinical trial, dose escalation | Watchlist company material event: sec filing, quarterly report", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Cullinan (w/ fred hutch)", "drug_name": "Cullinan", "event_type": "quarterly report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 10-q; quarterly report; Cullinan (w/ fred hutch); TCR/pMHC company watchlist entry; targets: \"novel senescence and cancer-related protein\"; Cullinan (w/ fred hutch); Cullinan; \"novel senescence and cancer-related protein\"; Cullinan; clinical trial; dose escalation; enrollment; clinical hold; FDA; EMA; liquidity; discontinued" }, { "digest_date": "2026-05-07", "window_start": "2026-05-06T05:15:00.000Z", "window_end": "2026-05-07T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 2, "score": 94, "id": "sec:0002000410:0001213900-26-052899:8-K", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/2000410/000121390026052899/ea0289458-8k425_eureka.htm", "headline": "Eureka Therapeutics: 8-K filing", "summary": "Eureka Therapeutics filed material event report on 2026-05-06. TCR/pMHC company watchlist entry; modalities: abTCR-T; targets: AFP, WT1", "url": "https://www.sec.gov/Archives/edgar/data/2000410/000121390026052899/ea0289458-8k425_eureka.htm", "source": "SEC EDGAR", "published_date": "2026-05-06", "match_reason": "Direct pMHC or peptide-MHC targeting: pmhc | Watchlist company material event: sec filing, 8-k, material event | Watchlist hits: TCR-T, WT1, AFP", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Eureka Therapeutics", "drug_name": "", "event_type": "material event report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 8-k; material event report; Eureka Therapeutics; TCR/pMHC company watchlist entry; modalities: abTCR-T; targets: AFP, WT1; Eureka Therapeutics; AFP; WT1" }, { "digest_date": "2026-05-07", "window_start": "2026-05-06T05:15:00.000Z", "window_end": "2026-05-07T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 3, "score": 82, "id": "sec:0001789972:0001193125-26-210290:8-K", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/1789972/000119312526210290/cgem-20260507.htm", "headline": "Cullinan (w/ fred hutch): 8-K filing", "summary": "Cullinan (w/ fred hutch) filed material event report on 2026-05-07. TCR/pMHC company watchlist entry; targets: \"novel senescence and cancer-related protein\"", "url": "https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-20260507.htm", "source": "SEC EDGAR", "published_date": "2026-05-07", "match_reason": "Direct pMHC or peptide-MHC targeting: pmhc | Watchlist company material event: sec filing, 8-k, material event", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Cullinan (w/ fred hutch)", "drug_name": "", "event_type": "material event report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 8-k; material event report; Cullinan (w/ fred hutch); TCR/pMHC company watchlist entry; targets: \"novel senescence and cancer-related protein\"; Cullinan (w/ fred hutch); Cullinan; \"novel senescence and cancer-related protein\"" }, { "digest_date": "2026-05-07", "window_start": "2026-05-06T05:15:00.000Z", "window_end": "2026-05-07T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 1, "score": 12, "id": "news:https://www.biopharmadive.com/news/bayer-perfuse-deal-glaucoma-diabetic-retinopathy-drug/819429/", "canonical_key": "url:https://www.biopharmadive.com/news/bayer-perfuse-deal-glaucoma-diabetic-retinopathy-drug/819429", "headline": "Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline", "summary": "Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020. ", "url": "https://www.biopharmadive.com/news/bayer-perfuse-deal-glaucoma-diabetic-retinopathy-drug/819429/", "source": "BioPharma Dive", "published_date": "2026-05-06T16:02:00.000Z", "match_reason": "LLM demotion: Bayer/Perfuse ophthalmology acquisition is general biotech M&A, not pMHC/TCR therapeutic news.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; news" }, { "digest_date": "2026-05-07", "window_start": "2026-05-06T05:15:00.000Z", "window_end": "2026-05-07T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 2, "score": 12, "id": "news:https://endpoints.news/gsk-goes-to-china-for-1b-sirna-deal-in-arrowheads-obesity-lane/", "canonical_key": "url:https://endpoints.news/gsk-goes-to-china-for-1b-sirna-deal-in-arrowheads-obesity-lane", "headline": "GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane", "summary": "GSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup. The UK pharma is teaming with Suzhou-based SiranBio, the little-known ...", "url": "https://endpoints.news/gsk-goes-to-china-for-1b-sirna-deal-in-arrowheads-obesity-lane/", "source": "Endpoints News", "published_date": "2026-05-06T13:39:55.000Z", "match_reason": "LLM demotion: GSK watchlist hit is obesity siRNA business news, not pMHC/TCR therapeutic news.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; news" }, { "digest_date": "2026-05-07", "window_start": "2026-05-06T05:15:00.000Z", "window_end": "2026-05-07T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 3, "score": 12, "id": "news:https://www.statnews.com/2026/05/06/sanofi-asks-to-pull-diabetes-drug-teplizumab-makary-fda-voucher-program/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/2026/05/06/sanofi-asks-to-pull-diabetes-drug-teplizumab-makary-fda-voucher-program", "headline": "STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review", "summary": "Sanofi has asked the FDA to pull its type 1 diabetes drug out of Commissioner Marty Makary’s new speedy drug review program.", "url": "https://www.statnews.com/2026/05/06/sanofi-asks-to-pull-diabetes-drug-teplizumab-makary-fda-voucher-program/?utm_campaign=rss", "source": "STAT Pharma", "published_date": "2026-05-06T16:16:42.000Z", "match_reason": "LLM demotion: Sanofi diabetes regulatory news is not pMHC/TCR therapeutic news.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "STAT Pharma", "secondary_coverage": "", "keywords": "news; STAT Pharma; regulatory" }, { "digest_date": "2026-05-08", "window_start": "2026-05-07T05:15:00.000Z", "window_end": "2026-05-08T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 100, "id": "sec:0001817713:0001193125-26-212146:10-Q", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/1817713/000119312526212146/janx-20260331.htm", "headline": "Janux: 10-Q filing", "summary": "Janux 10-Q highlights JANX007 and JANX008, including PSMA-targeted JANX007 in Phase 1 mCRPC; relevant as T-cell-engager/watchlist-adjacent clinical and filing context, not a direct pMHC/TCR program.", "url": "https://www.sec.gov/Archives/edgar/data/1817713/000119312526212146/janx-20260331.htm", "source": "SEC EDGAR", "published_date": "2026-05-07", "match_reason": "LLM summary rewrite: SEC 10-Q with named Janux T-cell-engager programs and PSMA Phase 1 context remains the clearest biotech-news item.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Janux", "drug_name": "JANX007, JANX008", "event_type": "quarterly report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 10-q; quarterly report; Janux; TCR/pMHC company watchlist entry; modalities: TCE (non TCR); targets: PSMA, EGFR; Janux; JANX007; JANX008; JANX007; JANX008; PSMA; EGFR; JANX007; JANX008; PSMA; clinical trial; enrollment; adverse event; clinical hold; FDA; EMA; liquidity; restructuring; termination" }, { "digest_date": "2026-05-08", "window_start": "2026-05-07T05:15:00.000Z", "window_end": "2026-05-08T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 2, "score": 36, "id": "news:https://www.biopharmadive.com/news/roche-to-acquire-digital-pathology-firm-pathai-in-deal-potentially-worth-ov/819592/", "canonical_key": "url:https://www.biopharmadive.com/news/roche-to-acquire-digital-pathology-firm-pathai-in-deal-potentially-worth-ov/819592", "headline": "Roche to acquire digital pathology firm PathAI in deal potentially worth over $1B", "summary": "Roche plans to acquire PathAI to add digital pathology tools for cancer diagnosis and tailored treatment; useful watchlist business context, but not a pMHC/TCR therapeutic event.", "url": "https://www.biopharmadive.com/news/roche-to-acquire-digital-pathology-firm-pathai-in-deal-potentially-worth-ov/819592/", "source": "BioPharma Dive", "published_date": "2026-05-07T14:55:35.000Z", "match_reason": "LLM rank exception: Roche oncology diagnostics acquisition is watchlist-relevant business context, but secondary to direct therapeutic/program events.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; news" }, { "digest_date": "2026-05-08", "window_start": "2026-05-07T05:15:00.000Z", "window_end": "2026-05-08T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 1, "score": 28, "id": "news:https://www.statnews.com/2026/05/07/fda-political-interference-sanofi-tzield-rfk-hhs-ssri/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/2026/05/07/fda-political-interference-sanofi-tzield-rfk-hhs-ssri", "headline": "STAT+: More political interference at the FDA?", "summary": "A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newsletter.", "url": "https://www.statnews.com/2026/05/07/fda-political-interference-sanofi-tzield-rfk-hhs-ssri/?utm_campaign=rss", "source": "STAT Pharma", "published_date": "2026-05-07T14:54:12.000Z", "match_reason": "", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "STAT Pharma", "secondary_coverage": "", "keywords": "news; STAT Pharma; regulatory" }, { "digest_date": "2026-05-08", "window_start": "2026-05-07T05:15:00.000Z", "window_end": "2026-05-08T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 2, "score": 28, "id": "news:https://www.statnews.com/pharmalot/2026/05/07/sanofi-diabetes-drug-voucher-fda-rethinking-rare-disease-rejection/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/pharmalot/2026/05/07/sanofi-diabetes-drug-voucher-fda-rethinking-rare-disease-rejection", "headline": "STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more", "summary": "Sanofi asked the FDA to pull teplizumab out of a speedy review voucher program after a political appointee disagreed with staff over its approval", "url": "https://www.statnews.com/pharmalot/2026/05/07/sanofi-diabetes-drug-voucher-fda-rethinking-rare-disease-rejection/?utm_campaign=rss", "source": "STAT Pharma", "published_date": "2026-05-07T13:47:21.000Z", "match_reason": "", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "STAT Pharma", "secondary_coverage": "", "keywords": "news; STAT Pharma; regulatory" }, { "digest_date": "2026-05-08", "window_start": "2026-05-07T05:15:00.000Z", "window_end": "2026-05-08T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 3, "score": 24, "id": "news:https://www.biopharmadive.com/news/angelini-catalyst-acquisition-cns-drugs/819591/", "canonical_key": "url:https://www.biopharmadive.com/news/angelini-catalyst-acquisition-cns-drugs/819591", "headline": "Angelini to buy Catalyst in $4B play for rare neuro drugs", "summary": "The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.", "url": "https://www.biopharmadive.com/news/angelini-catalyst-acquisition-cns-drugs/819591/", "source": "BioPharma Dive", "published_date": "2026-05-07T15:20:00.000Z", "match_reason": "", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; news" }, { "digest_date": "2026-05-08", "window_start": "2026-05-07T05:15:00.000Z", "window_end": "2026-05-08T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 4, "score": 12, "id": "news:https://endpoints.news/entrada-stock-falls-on-duchenne-data-wegovy-expands-access/", "canonical_key": "url:https://endpoints.news/entrada-stock-falls-on-duchenne-data-wegovy-expands-access", "headline": "Entrada stock falls on Duchenne data; Wegovy expands access", "summary": "Plus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...", "url": "https://endpoints.news/entrada-stock-falls-on-duchenne-data-wegovy-expands-access/", "source": "Endpoints News", "published_date": "2026-05-07T15:04:25.000Z", "match_reason": "LLM demotion: broad roundup with incidental GSK/Roche mentions, not a pMHC/TCR event.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; news" }, { "digest_date": "2026-05-08", "window_start": "2026-05-07T05:15:00.000Z", "window_end": "2026-05-08T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 5, "score": 12, "id": "news:https://endpoints.news/amgen-adds-300m-to-puerto-rico-budget-novartis-to-exit-oral-drug-factory-in-germany/", "canonical_key": "url:https://endpoints.news/amgen-adds-300m-to-puerto-rico-budget-novartis-to-exit-oral-drug-factory-in-germany", "headline": "Amgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany", "summary": "Plus, news about FDA's one-day inspections and BioMADE: 🇵🇷 Amgen pours another $300M into Puerto Rico: The funds will be used to bolster its biologics production in Juncos, which was established ...", "url": "https://endpoints.news/amgen-adds-300m-to-puerto-rico-budget-novartis-to-exit-oral-drug-factory-in-germany/", "source": "Endpoints News", "published_date": "2026-05-07T14:00:58.000Z", "match_reason": "LLM demotion: manufacturing/regulatory roundup with incidental Novartis mention, not a pMHC/TCR event.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; regulatory" }, { "digest_date": "2026-05-08", "window_start": "2026-05-07T05:15:00.000Z", "window_end": "2026-05-08T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 6, "score": 12, "id": "news:https://endpoints.news/astellas-touts-data-from-early-test-of-stem-cell-derived-eye-therapy/", "canonical_key": "url:https://endpoints.news/astellas-touts-data-from-early-test-of-stem-cell-derived-eye-therapy", "headline": "Astellas touts data from early test of stem cell-derived eye therapy", "summary": "Astellas reported promising results with its stem cell-derived therapy in an age-related eye disease, though data in a handful of high-dose patients in the early-stage study raised questions. The experimental stem cell therapy is made ...", "url": "https://endpoints.news/astellas-touts-data-from-early-test-of-stem-cell-derived-eye-therapy/", "source": "Endpoints News", "published_date": "2026-05-07T22:13:30.000Z", "match_reason": "LLM demotion: Astellas stem-cell ophthalmology readout is outside the TCR/pMHC focus.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; news" }, { "digest_date": "2026-05-09", "window_start": "2026-05-08T05:15:00.000Z", "window_end": "2026-05-09T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 24, "id": "news:https://endpoints.news/natalie-holles-next-move-after-third-harmonic-shutdown-mark-alles-passes-the-torch-at-adc-biotech/", "canonical_key": "url:https://endpoints.news/natalie-holles-next-move-after-third-harmonic-shutdown-mark-alles-passes-the-torch-at-adc-biotech", "headline": "Natalie Holles' next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotech", "summary": "→ It didn’t take long for Natalie Holles to rebound after the decision to wind down operations at her previous company. She has replaced Elisabet de los Pinos as CEO of ...", "url": "https://endpoints.news/natalie-holles-next-move-after-third-harmonic-shutdown-mark-alles-passes-the-torch-at-adc-biotech/", "source": "Endpoints News", "published_date": "2026-05-08T11:00:32.000Z", "match_reason": "Matched broad pMHC/TCR collection terms but needs editorial review.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "company distress", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; company distress" }, { "digest_date": "2026-05-12", "window_start": "2026-05-11T05:15:00.000Z", "window_end": "2026-05-12T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 1, "score": 12, "id": "news:https://endpoints.news/new-home-for-novos-parkinsons-cell-therapy-gsk-turns-to-china-for-hep-b-drug/", "canonical_key": "url:https://endpoints.news/new-home-for-novos-parkinsons-cell-therapy-gsk-turns-to-china-for-hep-b-drug", "headline": "New home for Novo's Parkinson's cell therapy; GSK's deal to sell drug in China", "summary": "Endpoints roundup mainly covering Novo Parkinson cell therapy and a GSK China marketing deal for bepirovirsen; watchlist-only and outside pMHC/TCR.", "url": "https://endpoints.news/new-home-for-novos-parkinsons-cell-therapy-gsk-turns-to-china-for-hep-b-drug/", "source": "Endpoints News", "published_date": "2026-05-11T15:11:26.000Z", "match_reason": "Editorial demotion: watchlist-only news outside pMHC/TCR scope", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "clinical data", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; clinical data" }, { "digest_date": "2026-05-12", "window_start": "2026-05-11T05:15:00.000Z", "window_end": "2026-05-12T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 2, "score": 12, "id": "news:https://www.biopharmadive.com/news/gsk-china-deal-sino-bepirovirsen-hepatitis-b/819818/", "canonical_key": "url:https://www.biopharmadive.com/news/gsk-china-deal-sino-bepirovirsen-hepatitis-b/819818", "headline": "GSK cuts deal with Sino to broaden reach of hepatitis B drug", "summary": "GSK/Sino marketing deal for hepatitis B drug bepirovirsen; watchlist-only business news, not pMHC/TCR or antigen-discovery material.", "url": "https://www.biopharmadive.com/news/gsk-china-deal-sino-bepirovirsen-hepatitis-b/819818/", "source": "BioPharma Dive", "published_date": "2026-05-11T15:56:10.000Z", "match_reason": "Editorial demotion: watchlist-only news outside pMHC/TCR scope", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; news" }, { "digest_date": "2026-05-12", "window_start": "2026-05-11T05:15:00.000Z", "window_end": "2026-05-12T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 3, "score": 12, "id": "news:https://www.statnews.com/2026/05/11/biotech-news-astellas-treatment-offers-hope-to-rare-disease-community/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/2026/05/11/biotech-news-astellas-treatment-offers-hope-to-rare-disease-community", "headline": "STAT+: Astellas treatment offers new hope to a devastated rare disease community", "summary": "STAT Readout item about Astellas rare-disease treatment context; watchlist-only signal and outside pMHC/TCR scope.", "url": "https://www.statnews.com/2026/05/11/biotech-news-astellas-treatment-offers-hope-to-rare-disease-community/?utm_campaign=rss", "source": "STAT Biotech", "published_date": "2026-05-11T14:45:46.000Z", "match_reason": "Editorial demotion: watchlist-only news outside pMHC/TCR scope", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "STAT Biotech", "secondary_coverage": "", "keywords": "news; STAT Biotech; news" }, { "digest_date": "2026-05-12", "window_start": "2026-05-11T05:15:00.000Z", "window_end": "2026-05-12T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 4, "score": 12, "id": "news:https://www.statnews.com/2026/05/11/astellas-gene-therapy-trials-resume-promising-myotubular-myopathy-treatment/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/2026/05/11/astellas-gene-therapy-trials-resume-promising-myotubular-myopathy-treatment", "headline": "STAT+: Five years after disaster, a rare disease community gets new chance at treatment", "summary": "Astellas XLMTM gene-therapy restart story after prior safety failures; watchlist-only and not pMHC/TCR-related.", "url": "https://www.statnews.com/2026/05/11/astellas-gene-therapy-trials-resume-promising-myotubular-myopathy-treatment/?utm_campaign=rss", "source": "STAT Biotech", "published_date": "2026-05-11T08:30:00.000Z", "match_reason": "Editorial demotion: watchlist-only news outside pMHC/TCR scope", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "STAT Biotech", "secondary_coverage": "", "keywords": "news; STAT Biotech; news" }, { "digest_date": "2026-05-14", "window_start": "2026-05-13T05:15:00.000Z", "window_end": "2026-05-14T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 42, "id": "clinicaltrials:NCT05005403", "canonical_key": "url:https://clinicaltrials.gov/study/nct05005403", "headline": "Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan", "summary": "Company: AbbVie | Drug/program: Azirkitug. Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.", "url": "https://clinicaltrials.gov/study/NCT05005403", "source": "ClinicalTrials.gov", "published_date": "2026-05-13", "match_reason": "Clinical or translational importance: clinical trial", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "AbbVie", "drug_name": "Azirkitug", "event_type": "clinical trial update", "primary_source": "ClinicalTrials.gov", "secondary_coverage": "", "keywords": "clinical trial; PHASE1; Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Micro Satellite Stable Colorectal Cancer; Gastric/Esophageal Cancer; High-Grade Serous Ovarian Cancer; Pancreatic Cancer; Triple Negative Breast Cancer; AbbVie; Azirkitug" }, { "digest_date": "2026-05-14", "window_start": "2026-05-13T05:15:00.000Z", "window_end": "2026-05-14T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 2, "score": 28, "id": "news:https://endpoints.news/abeona-pivots-to-t-cells-astrazenecas-rare-disease-drug-passes-phase-3/", "canonical_key": "url:https://endpoints.news/abeona-pivots-to-t-cells-astrazenecas-rare-disease-drug-passes-phase-3", "headline": "Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3", "summary": "Plus, news about Amicus Therapeutics, Fosun Pharma, Duality Biotherapeutics, BioNTech and C4 Therapeutics. 👁️ Abeona drops eye gene therapies, pivots to solid tumor T cell therapy: The biotech, which is known for marketing the rare ...", "url": "https://endpoints.news/abeona-pivots-to-t-cells-astrazenecas-rare-disease-drug-passes-phase-3/", "source": "Endpoints News", "published_date": "2026-05-13T15:36:52.000Z", "match_reason": "Watchlist hits: AstraZeneca", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; news" }, { "digest_date": "2026-05-14", "window_start": "2026-05-13T05:15:00.000Z", "window_end": "2026-05-14T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 3, "score": 28, "id": "news:https://endpoints.news/takeda-to-target-4500-jobs-as-incoming-ceo-continues-restructuring/", "canonical_key": "url:https://endpoints.news/takeda-to-target-4500-jobs-as-incoming-ceo-continues-restructuring", "headline": "Takeda to target 4,500 jobs as incoming CEO continues restructuring", "summary": "Takeda will cut roughly 9% of its workforce over the next fiscal year as the next CEO puts her stamp on a yearslong restructuring. About 4,500 roles will be affected, the company said Wednesday in ...", "url": "https://endpoints.news/takeda-to-target-4500-jobs-as-incoming-ceo-continues-restructuring/", "source": "Endpoints News", "published_date": "2026-05-13T18:36:06.000Z", "match_reason": "Watchlist hits: Takeda", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; news" }, { "digest_date": "2026-05-14", "window_start": "2026-05-13T05:15:00.000Z", "window_end": "2026-05-14T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 4, "score": 24, "id": "news:https://www.biopharmadive.com/news/assertio-zydus-isomorphic-ai-kyverna-ac-immune/819950/", "canonical_key": "url:https://www.biopharmadive.com/news/assertio-zydus-isomorphic-ai-kyverna-ac-immune/819950", "headline": "Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B", "summary": "Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.", "url": "https://www.biopharmadive.com/news/assertio-zydus-isomorphic-ai-kyverna-ac-immune/819950/", "source": "BioPharma Dive", "published_date": "2026-05-13T14:27:40.000Z", "match_reason": "Matched broad pMHC/TCR collection terms but needs editorial review.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "transaction", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; transaction" }, { "digest_date": "2026-05-15", "window_start": "2026-05-14T05:15:00.000Z", "window_end": "2026-05-15T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 100, "id": "sec:0001645460:0001193125-26-224091:10-Q", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/1645460/000119312526224091/cue-20260331.htm", "headline": "Cue Biopharma: 10-Q filing", "summary": "Cue Biopharma 10-Q flags pMHC platform/company watchlist relevance plus clinical-trial timing and financing/liquidity risk, including going-concern language.", "url": "https://www.sec.gov/Archives/edgar/data/1645460/000119312526224091/cue-20260331.htm", "source": "SEC EDGAR", "published_date": "2026-05-14", "match_reason": "Direct pMHC or peptide-MHC targeting: pmhc | Clinical or translational importance: clinical trial | Watchlist company material event: sec filing, quarterly report", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Cue Biopharma", "drug_name": "", "event_type": "quarterly report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 10-q; quarterly report; Cue Biopharma; TCR/pMHC company watchlist entry; Cue Biopharma; clinical trial; FDA; EMA; cash runway; going concern; substantial doubt; liquidity; termination" }, { "digest_date": "2026-05-15", "window_start": "2026-05-14T05:15:00.000Z", "window_end": "2026-05-15T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 1, "score": 12, "id": "news:https://www.statnews.com/pharmalot/2026/05/14/biogen-regenxbio-report-results-for-alzheimers-duchenne-takeda-layoffs/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/pharmalot/2026/05/14/biogen-regenxbio-report-results-for-alzheimers-duchenne-takeda-layoffs", "headline": "STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more", "summary": "STAT roundup includes Takeda layoffs alongside unrelated Biogen/Regenxbio updates; useful watchlist operating context only, not pMHC/TCR program news.", "url": "https://www.statnews.com/pharmalot/2026/05/14/biogen-regenxbio-report-results-for-alzheimers-duchenne-takeda-layoffs/?utm_campaign=rss", "source": "STAT Pharma", "published_date": "2026-05-14T13:44:43.000Z", "match_reason": "Watchlist-only news | Editorial demotion: watchlist-only / non-pMHC", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "STAT Pharma", "secondary_coverage": "", "keywords": "news; STAT Pharma; news" }, { "digest_date": "2026-05-15", "window_start": "2026-05-14T05:15:00.000Z", "window_end": "2026-05-15T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 2, "score": 12, "id": "news:https://endpoints.news/astrazeneca-follows-merck-with-phase-3-win-in-bladder-cancer/", "canonical_key": "url:https://endpoints.news/astrazeneca-follows-merck-with-phase-3-win-in-bladder-cancer", "headline": "AstraZeneca follows Merck with Phase 3 win in bladder cancer", "summary": "AstraZeneca/Pfizer/Astellas Padcev plus Imfinzi Phase 3 bladder cancer win; oncology watchlist context but not pMHC/TCR-specific.", "url": "https://endpoints.news/astrazeneca-follows-merck-with-phase-3-win-in-bladder-cancer/", "source": "Endpoints News", "published_date": "2026-05-14T14:31:59.000Z", "match_reason": "Watchlist-only news | Editorial demotion: watchlist-only / non-pMHC", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; regulatory" }, { "digest_date": "2026-05-15", "window_start": "2026-05-14T05:15:00.000Z", "window_end": "2026-05-15T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 3, "score": 12, "id": "news:https://endpoints.news/beones-next-gen-bcl2-inhibitor-wins-fda-approval-taking-aim-at-venclexta/", "canonical_key": "url:https://endpoints.news/beones-next-gen-bcl2-inhibitor-wins-fda-approval-taking-aim-at-venclexta", "headline": "BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta", "summary": "BeOne sonrotoclax approval positions a BCL2 drug against AbbVie/Roche Venclexta; Roche watchlist-only, outside pMHC/TCR.", "url": "https://endpoints.news/beones-next-gen-bcl2-inhibitor-wins-fda-approval-taking-aim-at-venclexta/", "source": "Endpoints News", "published_date": "2026-05-14T10:31:51.000Z", "match_reason": "Watchlist-only news | Editorial demotion: watchlist-only / non-pMHC", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; regulatory" }, { "digest_date": "2026-05-16", "window_start": "2026-05-15T05:15:00.000Z", "window_end": "2026-05-16T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 100, "id": "sec:0001107421:0001193125-26-227272:10-Q", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/1107421/000119312526227272/tcrt-20260331.htm", "headline": "Alaunos Therapeutics: 10-Q filing", "summary": "Alaunos quarterly filing; watchlist TCR-T/pMHC company update with clinical and financial context, but no clear new efficacy signal in the collected excerpt.", "url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312526227272/tcrt-20260331.htm", "source": "SEC EDGAR", "published_date": "2026-05-15", "match_reason": "Direct pMHC or peptide-MHC targeting: pmhc | Clinical or translational importance: clinical trial | Watchlist company material event: sec filing, quarterly report", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Alaunos Therapeutics", "drug_name": "", "event_type": "quarterly report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 10-q; quarterly report; Alaunos Therapeutics; TCR/pMHC company watchlist entry; Alaunos Therapeutics; clinical trial; EMA; cash runway; going concern; substantial doubt; liquidity; wind down" }, { "digest_date": "2026-05-16", "window_start": "2026-05-15T05:15:00.000Z", "window_end": "2026-05-16T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 2, "score": 94, "id": "sec:0002000410:0001213900-26-057674:10-Q", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/2000410/000121390026057674/ea0290469-10q_eureka.htm", "headline": "Eureka Therapeutics: 10-Q filing", "summary": "Eureka quarterly filing; watchlist cell-therapy company update with WT1/AFP/TCR-T language, but no clear new pMHC clinical data in the collected excerpt.", "url": "https://www.sec.gov/Archives/edgar/data/2000410/000121390026057674/ea0290469-10q_eureka.htm", "source": "SEC EDGAR", "published_date": "2026-05-15", "match_reason": "Direct pMHC or peptide-MHC targeting: pmhc | Watchlist company material event: sec filing, quarterly report | Watchlist hits: TCR-T, WT1, AFP", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Eureka Therapeutics", "drug_name": "", "event_type": "quarterly report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 10-q; quarterly report; Eureka Therapeutics; TCR/pMHC company watchlist entry; modalities: abTCR-T; targets: AFP, WT1; Eureka Therapeutics; AFP; WT1; EMA; going concern; substantial doubt; liquidity; termination" }, { "digest_date": "2026-05-16", "window_start": "2026-05-15T05:15:00.000Z", "window_end": "2026-05-16T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 3, "score": 28, "id": "news:https://www.biopharmadive.com/news/pazdur-fda-takeda-layoffs-astrazeneca-beone-alumis-acelyrin/820249/", "canonical_key": "url:https://www.biopharmadive.com/news/pazdur-fda-takeda-layoffs-astrazeneca-beone-alumis-acelyrin/820249", "headline": "Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers", "summary": "Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted immune drug.", "url": "https://www.biopharmadive.com/news/pazdur-fda-takeda-layoffs-astrazeneca-beone-alumis-acelyrin/820249/", "source": "BioPharma Dive", "published_date": "2026-05-15T15:36:00.000Z", "match_reason": "Watchlist hits: Takeda", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; regulatory" }, { "digest_date": "2026-05-16", "window_start": "2026-05-15T05:15:00.000Z", "window_end": "2026-05-16T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 4, "score": 28, "id": "news:https://www.statnews.com/pharmalot/2026/05/15/takeda-settle-allegations-kickbacks-to-doctors/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/pharmalot/2026/05/15/takeda-settle-allegations-kickbacks-to-doctors", "headline": "STAT+: Takeda will pay $13.6 million to settle allegations it paid kickbacks to doctors", "summary": "Takeda Pharmaceuticals agreed to pay $13.6 million to settle allegations that it paid kickbacks to doctors to prescribe an antidepressant.", "url": "https://www.statnews.com/pharmalot/2026/05/15/takeda-settle-allegations-kickbacks-to-doctors/?utm_campaign=rss", "source": "STAT Pharma", "published_date": "2026-05-15T17:41:45.000Z", "match_reason": "Watchlist hits: Takeda", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "STAT Pharma", "secondary_coverage": "", "keywords": "news; STAT Pharma; news" }, { "digest_date": "2026-05-16", "window_start": "2026-05-15T05:15:00.000Z", "window_end": "2026-05-16T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 5, "score": 24, "id": "news:https://www.biopharmadive.com/news/india-pharma-industry-china-drug-innovation/820335/", "canonical_key": "url:https://www.biopharmadive.com/news/india-pharma-industry-china-drug-innovation/820335", "headline": "India’s pharma industry is going global. But can it catch up to China?", "summary": "A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.", "url": "https://www.biopharmadive.com/news/india-pharma-industry-china-drug-innovation/820335/", "source": "BioPharma Dive", "published_date": "2026-05-15T13:00:40.000Z", "match_reason": "Matched broad pMHC/TCR collection terms but needs editorial review.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; news" }, { "digest_date": "2026-05-19", "window_start": "2026-05-18T05:15:00.000Z", "window_end": "2026-05-19T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 82, "id": "sec:0001107421:0001193125-26-227921:8-K", "canonical_key": "url:https://www.sec.gov/archives/edgar/data/1107421/000119312526227921/tcrt-20260302.htm", "headline": "Alaunos Therapeutics: 8-K filing", "summary": "Alaunos material event filing; watchlist pMHC/TCR-T company signal worth monitoring for corporate or financial implications, but not new therapeutic efficacy data.", "url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312526227921/tcrt-20260302.htm", "source": "SEC EDGAR", "published_date": "2026-05-18", "match_reason": "Direct pMHC or peptide-MHC targeting: pmhc | Watchlist company material event: sec filing, 8-k, material event", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Alaunos Therapeutics", "drug_name": "", "event_type": "material event report", "primary_source": "SEC EDGAR", "secondary_coverage": "", "keywords": "sec filing; 8-k; material event report; Alaunos Therapeutics; TCR/pMHC company watchlist entry; Alaunos Therapeutics" }, { "digest_date": "2026-05-19", "window_start": "2026-05-18T05:15:00.000Z", "window_end": "2026-05-19T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 2, "score": 42, "id": "clinicaltrials:NCT06948058", "canonical_key": "url:https://clinicaltrials.gov/study/nct06948058", "headline": "Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy", "summary": "Company: Brown University | Drug/program: Electronic Cigarettes (EC). This project will investigate the effects of alternative nicotine products on smoking, weight gain, and related outcomes.", "url": "https://clinicaltrials.gov/study/NCT06948058", "source": "ClinicalTrials.gov", "published_date": "2026-05-18", "match_reason": "Clinical or translational importance: clinical trial", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Brown University", "drug_name": "Electronic Cigarettes (EC)", "event_type": "clinical trial update", "primary_source": "ClinicalTrials.gov", "secondary_coverage": "", "keywords": "clinical trial; NA; Smoking Cessation; Obesity and Obesity-related Medical Conditions; Brown University; Electronic Cigarettes (EC)" }, { "digest_date": "2026-05-19", "window_start": "2026-05-18T05:15:00.000Z", "window_end": "2026-05-19T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 3, "score": 28, "id": "news:https://endpoints.news/fda-approves-astrazenecas-baxdrostat-for-certain-patients-with-hypertension/", "canonical_key": "url:https://endpoints.news/fda-approves-astrazenecas-baxdrostat-for-certain-patients-with-hypertension", "headline": "FDA approves AstraZeneca’s baxdrostat for certain patients with hypertension", "summary": "One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday. The blood ...", "url": "https://endpoints.news/fda-approves-astrazenecas-baxdrostat-for-certain-patients-with-hypertension/", "source": "Endpoints News", "published_date": "2026-05-18T10:01:41.000Z", "match_reason": "Watchlist hits: AstraZeneca", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; regulatory" }, { "digest_date": "2026-05-19", "window_start": "2026-05-18T05:15:00.000Z", "window_end": "2026-05-19T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 4, "score": 28, "id": "news:https://www.biopharmadive.com/news/astrazeneca-baxfendy-approval-hypertension-blood-pressure/820491/", "canonical_key": "url:https://www.biopharmadive.com/news/astrazeneca-baxfendy-approval-hypertension-blood-pressure/820491", "headline": "FDA approves AstraZeneca’s new kind of hypertension drug", "summary": "Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.", "url": "https://www.biopharmadive.com/news/astrazeneca-baxfendy-approval-hypertension-blood-pressure/820491/", "source": "BioPharma Dive", "published_date": "2026-05-18T16:04:00.000Z", "match_reason": "Watchlist hits: AstraZeneca", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; regulatory" }, { "digest_date": "2026-05-19", "window_start": "2026-05-18T05:15:00.000Z", "window_end": "2026-05-19T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 5, "score": 28, "id": "news:https://www.biopharmadive.com/news/hoeg-fda-amgen-vincentage-regeneron-parabilis/820451/", "canonical_key": "url:https://www.biopharmadive.com/news/hoeg-fda-amgen-vincentage-regeneron-parabilis/820451", "headline": "Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug", "summary": "The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.", "url": "https://www.biopharmadive.com/news/hoeg-fda-amgen-vincentage-regeneron-parabilis/820451/", "source": "BioPharma Dive", "published_date": "2026-05-18T14:49:00.000Z", "match_reason": "Watchlist hits: Regeneron", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; regulatory" }, { "digest_date": "2026-05-19", "window_start": "2026-05-18T05:15:00.000Z", "window_end": "2026-05-19T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 1, "score": 28, "id": "news:https://www.biopharmadive.com/news/regeneron-cancer-immunotherapy-fianlimab-lag3-melanoma-study-results/820443/", "canonical_key": "url:https://www.biopharmadive.com/news/regeneron-cancer-immunotherapy-fianlimab-lag3-melanoma-study-results/820443", "headline": "Regeneron immunotherapy combo comes up short in melanoma trial", "summary": "A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.", "url": "https://www.biopharmadive.com/news/regeneron-cancer-immunotherapy-fianlimab-lag3-melanoma-study-results/820443/", "source": "BioPharma Dive", "published_date": "2026-05-18T11:55:00.000Z", "match_reason": "Watchlist hits: Regeneron", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; news" }, { "digest_date": "2026-05-19", "window_start": "2026-05-18T05:15:00.000Z", "window_end": "2026-05-19T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 2, "score": 28, "id": "news:https://endpoints.news/regeneron-reaches-125m-parabilis-deal-for-hard-to-catch-drug-targets/", "canonical_key": "url:https://endpoints.news/regeneron-reaches-125m-parabilis-deal-for-hard-to-catch-drug-targets", "headline": "Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets", "summary": "As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a deal with Parabilis Medicines valued at as much as $2.2 billion. Parabilis is focused on ...", "url": "https://endpoints.news/regeneron-reaches-125m-parabilis-deal-for-hard-to-catch-drug-targets/", "source": "Endpoints News", "published_date": "2026-05-18T15:33:27.000Z", "match_reason": "Watchlist hits: Regeneron", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; news" }, { "digest_date": "2026-05-19", "window_start": "2026-05-18T05:15:00.000Z", "window_end": "2026-05-19T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 3, "score": 28, "id": "news:https://endpoints.news/regenerons-phase-3-skin-cancer-miss-adds-to-mounting-failures-in-lag-3/", "canonical_key": "url:https://endpoints.news/regenerons-phase-3-skin-cancer-miss-adds-to-mounting-failures-in-lag-3", "headline": "Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3", "summary": "Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a spate of recent clinical setbacks for candidates targeting the LAG-3 ...", "url": "https://endpoints.news/regenerons-phase-3-skin-cancer-miss-adds-to-mounting-failures-in-lag-3/", "source": "Endpoints News", "published_date": "2026-05-18T10:34:21.000Z", "match_reason": "Watchlist hits: Regeneron", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; news" }, { "digest_date": "2026-05-19", "window_start": "2026-05-18T05:15:00.000Z", "window_end": "2026-05-19T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 4, "score": 28, "id": "news:https://www.statnews.com/2026/05/18/biotech-news-astrazeneca-picks-up-fda-approval-hypertension-drug/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/2026/05/18/biotech-news-astrazeneca-picks-up-fda-approval-hypertension-drug", "headline": "STAT+: AstraZeneca picks up FDA approval for hypertension drug", "summary": "The China question, FDA leadership shakeups, and other biotech news from The Readout", "url": "https://www.statnews.com/2026/05/18/biotech-news-astrazeneca-picks-up-fda-approval-hypertension-drug/?utm_campaign=rss", "source": "STAT Biotech", "published_date": "2026-05-18T17:05:01.000Z", "match_reason": "Watchlist hits: AstraZeneca", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "STAT Biotech", "secondary_coverage": "", "keywords": "news; STAT Biotech; regulatory" }, { "digest_date": "2026-05-19", "window_start": "2026-05-18T05:15:00.000Z", "window_end": "2026-05-19T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 5, "score": 28, "id": "news:https://www.statnews.com/pharmalot/2026/05/18/biotech-has-china-problem-regeneron-melanoma-drug-flops/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/pharmalot/2026/05/18/biotech-has-china-problem-regeneron-melanoma-drug-flops", "headline": "STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more", "summary": "The question of whether to partner with Chinese firms — or see them as rivals — is tearing biotech apart, pitting peers and partners against one another", "url": "https://www.statnews.com/pharmalot/2026/05/18/biotech-has-china-problem-regeneron-melanoma-drug-flops/?utm_campaign=rss", "source": "STAT Pharma", "published_date": "2026-05-18T13:11:48.000Z", "match_reason": "Watchlist hits: Regeneron", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "STAT Pharma", "secondary_coverage": "", "keywords": "news; STAT Pharma; news" }, { "digest_date": "2026-05-19", "window_start": "2026-05-18T05:15:00.000Z", "window_end": "2026-05-19T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 6, "score": 28, "id": "news:https://endpoints.news/the-supreme-court-wont-take-up-drugmakers-ira-cases/", "canonical_key": "url:https://endpoints.news/the-supreme-court-wont-take-up-drugmakers-ira-cases", "headline": "The Supreme Court won't take up drugmakers' IRA cases", "summary": "The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca, Johnson & ...", "url": "https://endpoints.news/the-supreme-court-wont-take-up-drugmakers-ira-cases/", "source": "Endpoints News", "published_date": "2026-05-18T14:32:27.000Z", "match_reason": "Watchlist hits: AstraZeneca", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; news" }, { "digest_date": "2026-05-20", "window_start": "2026-05-19T05:15:00.000Z", "window_end": "2026-05-20T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 1, "score": 28, "id": "news:https://www.biopharmadive.com/news/relay-zovegalisib-vascular-anomalies-study-results/820532/", "canonical_key": "url:https://www.biopharmadive.com/news/relay-zovegalisib-vascular-anomalies-study-results/820532", "headline": "Relay drug shows early promise against rare blood vessel diseases", "summary": "While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.", "url": "https://www.biopharmadive.com/news/relay-zovegalisib-vascular-anomalies-study-results/820532/", "source": "BioPharma Dive", "published_date": "2026-05-19T12:05:00.000Z", "match_reason": "Watchlist hits: Novartis", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; news" }, { "digest_date": "2026-05-20", "window_start": "2026-05-19T05:15:00.000Z", "window_end": "2026-05-20T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 2, "score": 24, "id": "news:https://www.biopharmadive.com/news/mentari-inmed-deal-acquisition-migraine-combined-company/820610/", "canonical_key": "url:https://www.biopharmadive.com/news/mentari-inmed-deal-acquisition-migraine-combined-company/820610", "headline": "A migraine drugmaker heads to the public markets through reverse merger", "summary": "Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.", "url": "https://www.biopharmadive.com/news/mentari-inmed-deal-acquisition-migraine-combined-company/820610/", "source": "BioPharma Dive", "published_date": "2026-05-19T15:19:00.000Z", "match_reason": "Matched broad pMHC/TCR collection terms but needs editorial review.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "transaction", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; transaction" }, { "digest_date": "2026-05-20", "window_start": "2026-05-19T05:15:00.000Z", "window_end": "2026-05-20T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "top", "rank_index": 3, "score": 24, "id": "news:https://www.biopharmadive.com/news/biomarins-enpp1-deficiency-inozyme-study-results/820585/", "canonical_key": "url:https://www.biopharmadive.com/news/biomarins-enpp1-deficiency-inozyme-study-results/820585", "headline": "BioMarin drug acquired in buyout misses goal in rare disease study", "summary": "Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects. ", "url": "https://www.biopharmadive.com/news/biomarins-enpp1-deficiency-inozyme-study-results/820585/", "source": "BioPharma Dive", "published_date": "2026-05-19T15:58:00.000Z", "match_reason": "Matched broad pMHC/TCR collection terms but needs editorial review.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "transaction", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; transaction" }, { "digest_date": "2026-05-21", "window_start": "2026-05-20T05:15:00.000Z", "window_end": "2026-05-21T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 1, "score": 3, "id": "news:https://endpoints.news/parabilis-reveals-ipo-plans-the-day-after-regeneron-deal-as-listings-heat-up/", "canonical_key": "url:https://endpoints.news/parabilis-reveals-ipo-plans-the-day-after-regeneron-deal-as-listings-heat-up", "headline": "Parabilis reveals IPO plans the day after Regeneron deal as listings heat up", "summary": "Parabilis Medicines, the decade-old and well-funded \"undruggable\" biotech out of Greg Verdine's Harvard lab, seeks to become the 12th drug developer to conduct an initial public offering this year. The biotech", "url": "https://endpoints.news/parabilis-reveals-ipo-plans-the-day-after-regeneron-deal-as-listings-heat-up/", "source": "Endpoints News", "published_date": "2026-05-20T10:40:54.000Z", "match_reason": "Watchlist hits: Regeneron", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; news" }, { "digest_date": "2026-05-22", "window_start": "2026-05-21T05:15:00.000Z", "window_end": "2026-05-22T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 1, "score": 6, "id": "news:https://endpoints.news/bms-eyes-new-campus-in-texas-novartis-looks-to-evict-tenant-at-slovenian-campus/", "canonical_key": "url:https://endpoints.news/bms-eyes-new-campus-in-texas-novartis-looks-to-evict-tenant-at-slovenian-campus", "headline": "BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus", "summary": "Plus, news about Gilead and West Pharma: 🏭Bristol Myers Squibb looks to Texas: The drugmaker is considering building a new pharma campus in Generation Park Management District in Houston, TX, which ...", "url": "https://endpoints.news/bms-eyes-new-campus-in-texas-novartis-looks-to-evict-tenant-at-slovenian-campus/", "source": "Endpoints News", "published_date": "2026-05-21T13:02:14.000Z", "match_reason": "Watchlist hits: BMS, Novartis", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; news" }, { "digest_date": "2026-05-22", "window_start": "2026-05-21T05:15:00.000Z", "window_end": "2026-05-22T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 2, "score": 3, "id": "news:https://endpoints.news/new-data-released-for-vegf-bispecifics-from-biontech-bms-pfizer-3sbio/", "canonical_key": "url:https://endpoints.news/new-data-released-for-vegf-bispecifics-from-biontech-bms-pfizer-3sbio", "headline": "#ASCO26: New data released for VEGF bispecifics from BioNTech-BMS, Pfizer-3SBio", "summary": "Company: T Therapeutics. Much of the attention heading into the annual ASCO meeting next week has focused on Summit Therapeutics and Akeso’s plenary presentation for their bispecific drug ivonescimab. But two of ivonescimab’s biggest competitors are also releasing ...", "url": "https://endpoints.news/new-data-released-for-vegf-bispecifics-from-biontech-bms-pfizer-3sbio/", "source": "Endpoints News", "published_date": "2026-05-21T21:00:09.000Z", "match_reason": "Watchlist hits: BMS", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "T Therapeutics", "drug_name": "", "event_type": "news", "primary_source": "Endpoints News", "secondary_coverage": "", "keywords": "news; Endpoints News; T Therapeutics; news" }, { "digest_date": "2026-05-22", "window_start": "2026-05-21T05:15:00.000Z", "window_end": "2026-05-22T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 3, "score": 0, "id": "news:https://www.statnews.com/2026/05/21/biotech-news-immunovant-shares-surge-on-arthritis-trial-data/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/2026/05/21/biotech-news-immunovant-shares-surge-on-arthritis-trial-data", "headline": "STAT+: Immunovant shares surge on arthritis trial data", "summary": "Trial results for Lilly's \"triple-G\" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout", "url": "https://www.statnews.com/2026/05/21/biotech-news-immunovant-shares-surge-on-arthritis-trial-data/?utm_campaign=rss", "source": "STAT Biotech", "published_date": "2026-05-21T16:27:38.000Z", "match_reason": "No high-specificity pMHC/TCR ranking signal detected.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "clinical data", "primary_source": "STAT Biotech", "secondary_coverage": "", "keywords": "news; STAT Biotech; clinical data" }, { "digest_date": "2026-05-23", "window_start": "2026-05-22T17:15:00.000Z", "window_end": "2026-05-23T19:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 1, "score": 0, "id": "clinicaltrials:NCT07602777", "canonical_key": "url:https://clinicaltrials.gov/study/nct07602777", "headline": "A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)", "summary": "Company: GlaxoSmithKline | Drug/program: Ris-Rez. The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it, and how their bodies handle th...", "url": "https://clinicaltrials.gov/study/NCT07602777", "source": "ClinicalTrials.gov", "published_date": "2026-05-22", "match_reason": "No high-specificity pMHC/TCR ranking signal detected.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "GlaxoSmithKline", "drug_name": "Ris-Rez", "event_type": "clinical trial update", "primary_source": "ClinicalTrials.gov", "secondary_coverage": "", "keywords": "clinical trial; PHASE1; PHASE2; Sarcoma; GlaxoSmithKline; Ris-Rez" }, { "digest_date": "2026-05-26", "window_start": "2026-05-25T17:15:00.000Z", "window_end": "2026-05-26T19:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 1, "score": 3, "id": "news:https://www.biopharmadive.com/news/astellas-cuts-moderna-fda-datroway-tnbc-hepcludex-hepatitis/821055/", "canonical_key": "url:https://www.biopharmadive.com/news/astellas-cuts-moderna-fda-datroway-tnbc-hepcludex-hepatitis/821055", "headline": "Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine", "summary": "The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.", "url": "https://www.biopharmadive.com/news/astellas-cuts-moderna-fda-datroway-tnbc-hepcludex-hepatitis/821055/", "source": "BioPharma Dive", "published_date": "2026-05-26T14:16:57.000Z", "match_reason": "Watchlist hits: Astellas", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; regulatory" }, { "digest_date": "2026-05-26", "window_start": "2026-05-25T17:15:00.000Z", "window_end": "2026-05-26T19:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 2, "score": 0, "id": "news:https://www.biopharmadive.com/news/lilly-deal-acquire-curevo-limmatech-vaccine/821064/", "canonical_key": "url:https://www.biopharmadive.com/news/lilly-deal-acquire-curevo-limmatech-vaccine/821064", "headline": "Lilly dives into vaccine research with 3 biotech buyouts", "summary": "Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.", "url": "https://www.biopharmadive.com/news/lilly-deal-acquire-curevo-limmatech-vaccine/821064/", "source": "BioPharma Dive", "published_date": "2026-05-26T15:48:00.000Z", "match_reason": "No high-specificity pMHC/TCR ranking signal detected.", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; news" }, { "digest_date": "2026-05-28", "window_start": "2026-05-27T05:15:00.000Z", "window_end": "2026-05-28T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 1, "score": 6, "id": "news:https://www.statnews.com/pharmalot/2026/05/27/astrazeneca-breast-cancer-pill-adap-deal-in-florida/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/pharmalot/2026/05/27/astrazeneca-breast-cancer-pill-adap-deal-in-florida", "headline": "STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more", "summary": "Company: Adaptimmune. The FDA extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel voted against the drug", "url": "https://www.statnews.com/pharmalot/2026/05/27/astrazeneca-breast-cancer-pill-adap-deal-in-florida/?utm_campaign=rss", "source": "STAT Pharma", "published_date": "2026-05-27T13:33:27.000Z", "match_reason": "Watchlist hits: Adaptimmune, AstraZeneca", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "Adaptimmune", "drug_name": "", "event_type": "regulatory", "primary_source": "STAT Pharma", "secondary_coverage": "", "keywords": "news; STAT Pharma; Adaptimmune; regulatory" }, { "digest_date": "2026-05-28", "window_start": "2026-05-27T05:15:00.000Z", "window_end": "2026-05-28T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 2, "score": 3, "id": "news:https://www.biopharmadive.com/news/astrazeneca-camizestrant-fda-delay-breast-cancer/821193/", "canonical_key": "url:https://www.biopharmadive.com/news/astrazeneca-camizestrant-fda-delay-breast-cancer/821193", "headline": "FDA delays decision on AstraZeneca breast cancer pill", "summary": "The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive in what would be a new kind of treatment setting.", "url": "https://www.biopharmadive.com/news/astrazeneca-camizestrant-fda-delay-breast-cancer/821193/", "source": "BioPharma Dive", "published_date": "2026-05-27T18:09:00.000Z", "match_reason": "Watchlist hits: AstraZeneca", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "regulatory", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; regulatory" }, { "digest_date": "2026-05-28", "window_start": "2026-05-27T05:15:00.000Z", "window_end": "2026-05-28T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 3, "score": 3, "id": "news:https://www.biopharmadive.com/news/kardigan-ipo-filing-biotech-cardiovascular-heart-drug/821233/", "canonical_key": "url:https://www.biopharmadive.com/news/kardigan-ipo-filing-biotech-cardiovascular-heart-drug/821233", "headline": "Cardio drugmaker Kardigan plans to go public", "summary": "Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.", "url": "https://www.biopharmadive.com/news/kardigan-ipo-filing-biotech-cardiovascular-heart-drug/821233/", "source": "BioPharma Dive", "published_date": "2026-05-27T16:07:00.000Z", "match_reason": "Watchlist hits: Sanofi", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; news" }, { "digest_date": "2026-05-29", "window_start": "2026-05-28T05:15:00.000Z", "window_end": "2026-05-29T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 1, "score": 3, "id": "news:https://www.biopharmadive.com/news/gsk-ionis-bepirovirsen-hepatitis-b-nejm-study-results/821341/", "canonical_key": "url:https://www.biopharmadive.com/news/gsk-ionis-bepirovirsen-hepatitis-b-nejm-study-results/821341", "headline": "GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’", "summary": "The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.", "url": "https://www.biopharmadive.com/news/gsk-ionis-bepirovirsen-hepatitis-b-nejm-study-results/821341/", "source": "BioPharma Dive", "published_date": "2026-05-28T16:01:00.000Z", "match_reason": "Watchlist hits: GSK", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "BioPharma Dive", "secondary_coverage": "", "keywords": "news; BioPharma Dive; news" }, { "digest_date": "2026-05-29", "window_start": "2026-05-28T05:15:00.000Z", "window_end": "2026-05-29T07:15:00.000Z", "source_type": "biotech_news", "rank_bucket": "lower_priority", "rank_index": 2, "score": 3, "id": "news:https://www.statnews.com/2026/05/28/biotech-news-asco-preview-2026-all-eyes-on-pancreatic-cancer/?utm_campaign=rss", "canonical_key": "url:https://www.statnews.com/2026/05/28/biotech-news-asco-preview-2026-all-eyes-on-pancreatic-cancer", "headline": "STAT+: Ahead of ASCO, all eyes on pancreatic cancer", "summary": "Strong results from GSK's hepatitis B drug, engineered heart patches, and more biotech news from The Readout", "url": "https://www.statnews.com/2026/05/28/biotech-news-asco-preview-2026-all-eyes-on-pancreatic-cancer/?utm_campaign=rss", "source": "STAT Biotech", "published_date": "2026-05-28T13:21:44.000Z", "match_reason": "Watchlist hits: GSK", "journal": "", "pmid": "", "doi": "", "preprint_id": "", "authors": "", "assignee": "", "publication_number": "", "jurisdiction": "", "claims": "", "company_name": "", "drug_name": "", "event_type": "news", "primary_source": "STAT Biotech", "secondary_coverage": "", "keywords": "news; STAT Biotech; news" } ]